Galectin Therapeutics, Inc (GALT) Stock Price

2.38 ▲ +0.03 (+1.28%)
Open: 2.35 Vol: 111.4K Day's range: 2.345 - 2.45 Jun 04, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
GALT Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY SELL NEUTRAL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 2.37▼ 2.36▲ 2.37▲ 2.46▼ 2.33▲
MA10 2.36▲ 2.38▼ 2.37▲ 2.54▼ 2.37▲
MA20 2.36▲ 2.37▲ 2.39▼ 2.36▲ 2.65▼
MA50 2.38▼ 2.45▼ 2.53▼ 2.40▼ 3.65▼
MA100 2.37▼ 2.57▼ 2.44▼ 2.71▼ 2.78▼
MA200 2.46▼ 2.44▼ 2.35▲ 3.82▼ 2.33▲
  5 mins 30 mins Hourly Daily Weekly
MACD 0.003▲ 0.004▲ 0.006▲ 0.007▲ 0.010▲
RSI 52.385▲ 45.035▼ 42.263▼ 48.686▼ 39.927▼
STOCH 88.333▲ 21.569     43.803     34.480     24.938    
WILL %R -25.000▲ -72.727     -59.259     -70.048     -75.932▼
CCI 71.591     -50.129     8.000     -20.076     -28.665    
Latest Filters Detected On GALT
RSI $GALT RSI(14) Crossed Below 50 Set Alert
MA $GALT Price Crossed Below MA(50) Set Alert
MA $GALT Price Crossed Below MA(13) Set Alert
MA $GALT Price Crossed Below MA(7) Set Alert
Galectin Therapeutics, Inc News
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Sunday, May 31, 2026 04:06 AM
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ...
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Wednesday, May 27, 2026 05:26 AM
Data from the NAVIGATE trial presented at EASL 2026 (May 27–30, Barcelona) oral presentation demonstrates belapectin reduces varices development in high-risk MASH cirrhosis by modulating fibrogenesis ...
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Monday, May 11, 2026 05:13 AM
Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today ...
GALT historical stock data
date open high low close volume
04/06/26 2.35 2.45 2.345 2.38 111,400
03/06/26 2.43 2.43 2.31 2.35 226,090
02/06/26 2.60 2.63 2.40 2.42 278,896
01/06/26 2.56 2.70 2.50 2.61 315,124
29/05/26 2.60 2.60 2.43 2.52 282,315
28/05/26 2.78 2.78 2.565 2.57 348,421
27/05/26 2.82 2.85 2.67 2.70 422,636
26/05/26 2.57 3.105 2.525 2.79 977,487
22/05/26 2.52 2.6299 2.4855 2.50 300,199
21/05/26 2.20 2.56 2.15 2.52 390,743
Quote Details
52wk Low:1.28
52wk High:7.13
Vol:111.4K
Avg Vol(3m):5.2M
1Y Chng:-4.03%
1M Chng:+0.42%
Add to Watch List
More Information
Index US Composite
Market Cap. 154.76M